RAPPORT : Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

Male or<br/>FemaleGender Male or
Female

Closed (no longer recruiting)Status Closed (no longer recruiting)

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

One/TwoPhase One/Two

18+Age Over 18

Kidney<br/>CancersCancer LocationKidney
Cancers

Multiple treatment types,Radiotherapy,Systemic therapy | Urinary systemKidney,Renal cell carcinoma

Trial Overview Read MoreRead more

This phase I/II trial is evaluating a radiotherapy-immunotherapy combination to treat kidney cancers that have spread to other parts of the body.
 

This trial is treating patients with kidney cancer.

This is a systemic therapy and radiotherapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

Patients will receive Stereotactic Radiotherapy (SABR, 180Gy-20Gy/1#) followed by intravenous pembrolizumab at a dose of 200mg every 3 weeks for a total of 8 cycles.

Not Recruiting Hospitals Read MoreRead more

Closed

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next